2023
TDR and WHO announce TDA4Child, an operational research package to generate data on treatment decision algorithms for pulmonary tuberculosis in children
TB Vaccine Candidate Plans Efficacy Study
JOINT STATEMENT: WHO DIRECTOR-GENERAL AND THE CIVIL SOCIETY TASK FORCE ON TB FOR THE 2023 UNITED NATIONS HIGH-LEVEL MEETING ON TUBERCULOSIS
Mycobacterium Tuberculosis Treatment Market Size, Analysis, Growth ratio, Top Players and Future Forecasts to 2022-2029
Task Force Recommends Latent TB Infection Screening
Understanding TB Laboratory Testing for Public Health Nurses
Preguntas Frecuentes: La Tuberculosis (TB) [Frequently Asked Questions: Tuberculosis (TB)]
Screening for Latent Tuberculosis Infection in AdultsUS Preventive Services Task Force Recommendation Statement
Uniting for Ukraine Tuberculosis Screening Experience, San Francisco, California, USA
Hope away from home: Providing support for refugees with tuberculosis, wherever they live
Outcomes from a national screening program for Ukrainian refugees at risk of drug resistant tuberculosis in Wales
Tuberculosis Outbreak Among Monkeys in Michigan Laboratory
CDC Quarantine Fails to Detect TB Outbreak; PETA Urges Immediate Action
Joint Statement from the United States and India
Novel device holds promise for diagnosing tuberculosis in the “missing millions”
Launch of a second wave of IJTLD Clinical Standards for Lung Health
READY NEXT TIME Beating TB today and preparing for pandemics tomorrow
QIAGEN’s QuantiFERON-TB Gold Plus shows unique clinical value with CD8 technology in new meta-analysis of tuberculosis screening
TB Notes 2, 2023
TB is Still Here – New CDC Data Show U.S. Cases Increased Again in 2022
With TB Response Rebounding from the COVID-19 Pandemic Downturn, Prime Minister Modi Marks the Start of a New Era on World TB Day:Yes! We Can End TB
TB Faded During Covid But Now It’s Back, CDC Data Shows
Validation of rapid, molecular testing for COVID-19 and integration with TB diagnostics
Short, Effective Drug-Resistant TB Treatment for All Starts Here!
WHO Director-General Flagship Initiative to #ENDTB 2023-2027
Ending Tuberculosis - the role of Europe in responding to growing challenges
Need for increased global attention on maternal TB: Global TB Report inclusion
2022
WHO announces plans to establish a TB Vaccine Accelerator council
Worldwide TB R&D Funding Surpasses US$1 Billion, But Falls Short of Goals
Innovative trial finds better treatment for people with drug-resistant TB
Price reduction paves the way for expanded access to highly effective multidrug-resistant tuberculosis treatment
TB-PRACTECAL: Groundbreaking MSF trial finds better treatment for people with drug-resistant tuberculosis
LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test
Innovative TB Community Service Delivery during the COVID-19 Pandemic: Best Practices and Lessons Learned from Cambodia, India, Indonesia, and Kenya
WHO announces landmark changes in treatment of drug-resistant tuberculosis
WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update
FACT SHEET: U.S-Africa Partnership in Health Cooperation
Response to TB treatment trials results published and presented during the 2022 Union World Conference on Lung Health
Pipeline Report » 2022 Tuberculosis Diagnostics
New MSF report warns that major opportunity to increase access to newer, safer DR-TB drugs is at risk
An investment case for new tuberculosis vaccines
Tuberculosis Research Funding Trends 2005 — 2021
WORLDWIDE TB R&D FUNDING SURPASSES US$1 BILLION, BUT FALLS SHORT OF GOALS
Transformative solutions for equitable access to TB services for persons with disabilities
Tuberculosis deaths and disease increase during the COVID-19 pandemic
Global Tuberculosis Report 2022
USAID ANNOUNCES EIGHT-YEAR STRATEGY TO END TUBERCULOSIS
Global meeting on strengthening public-private provider engagement calls for greater collaboration with all care providers to get the TB response back-on-track and to enhance accountability
Global Fund Board Hails Record-Breaking Seventh Replenishment Final Outcome of US$15.7 Billion
Tuberculosis voice at the G20 - Stop TB Partnership
1/4/6×24 Campaign
Public Health Leaders, Researchers, and Activists Launch Global Campaign to Revolutionize Tuberculosis Prevention and Treatmnt with New, Shorter, Stronger, Safer, Evidence-Based Regimens
Overview of Notice of Funding Opportunity: Advancing Policy as a Public Health Intervention to Reduce Morbidity, Mortality and Disparities in HIV, Viral Hepatitis, STDs, and Tuberculosis; PS-23-0009
DR-TB Drugs Under the Microscope, 8th Edition
Pipeline Report » 2022 : Tuberculosis Diagnostics
TB Deaths Up Again: Ask Congress to Pass the End TB Now Act
UNGA 77: STOP TB HIGHLIGHTS THE NEED FOR ENDING TB
Lupin Partners with Global Agencies to Increase Patient Access to Tuberculosis Prevention Treatment
Illumina and GenoScreen Partner to Expand Access to Genomic Testing for Multidrug-Resistant Tuberculosis
Merck and the Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Tuberculosis Antibiotic Candidates
Parliamentarians and Civil Society align on key issues around TB in Migration
PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test
Diversifying the next generation of TB vaccines
WHO announces updates to its guidelines on tests for the diagnosis of TB infection
Four Years Down, One to Go: The Road to the 2023 UN High-Level Meeting on TB
TB Alliance Statement on New World Health Organization Rapid Communication on Key Changes to the Treatment of Drug-Resistant Tuberculosis
MSF warns that supply delays of critical TB test will cost lives
The Global Fund Results Report 2022
TB action plan for the WHO European Region 2023–2030
TB Notes 3, 2022: Notes from the Director
The Stop TB Partnership call on governments of donor and high burden TB countries to pledge at least US$18 billion to Global Fund and triple domestic investments in TB
U.S. SUPPORTS QUEZON CITY IN FIGHT AGAINST TUBERCULOSIS AND COVID-19
Addressing Tuberculosis and Latent Tuberculosis Infection Screening, Testing, and Treatment Needs Among Community Health Centers Serving Asian Americans, Native Hawaiians, and Pacific Islanders – September 2022
PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials
BioNTech selects Rwanda, Senegal for potential malaria and tuberculosis mRNA vaccine manufacturing
High Rates of Chronic Hepatitis B and Tuberculosis Co-Infection Observed in Nationally Representative Quest Diagnostics Study
Mid-term Assessment Summary Report: Global Fund Breaking Down Barriers Initiative, July 2022
Community, rights and gender investment packages
2022 SPECIAL REPORT: COVID-19 - U.S. IMPACT ON ANTIMICROBIAL RESISTANCE
Bacterial vaccines in clinical and preclinical development 2021: An overview and analysis
GLOBAL PLAN TO END TB 2023-2030
New, multi-year US$ 5.5 million project will “Re-imagine TB Care”
People-Centered, Rights-Based TB Legislation In Eastern Europe and Central Asia
Lack of access to medicine is a major driver of drug resistance. How can pharma take action?
Drug-Resistant Tuberculosis Treatment Market Is Expected to Boom| Sanofi, Novartis AG, Endo International plc, CMP Pharma
WHO Director-General's keynote address at the WHO Global Tuberculosis Programme – 9 June 2022
WHO convenes experts to review methods for estimating TB disease burden
U.S. Government Funded Research Brings Shorter Tuberculosis Treatment Regimens to New York City
Joint Delegation Statement of Community, Developing Country NGOs and Developed Country NGOs
DIGITAL TB SURVEILLANCE SYSTEM ASSESSMENT REPORT
Davos booster for $18 billion fund to fight AIDS, tuberculosis and malaria
Rapid communication: Key changes to the treatment of drug-resistant tuberculosis (who.int)
New details behind the body’s response to tuberculosis could lead to a more effective vaccine
Consolidated report of country success stories in mitigating the impact of the COVID-19 pandemic on TB services
2022 Epidemic Intelligence Service (EIS) Conference
Methods combine to decode the biology of tuberculosis
Tuberculosis Treatment Drugs Market to See Drastic Growth – Post 2022 | Pfizer, Mylan, Sanofi
Global Fund Strategy (2023-2028)
Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure
Management of childhood MDR-TB in Europe and Central Asia: report of a Regional WHO meeting
Stop TB Partnership - World TB Day 2022 Campaign Update
IAVI AND MODERNA PARTNER TO TACKLE BROAD GLOBAL HEALTH PRIORITIES USING MRNA FOR VACCINES AND ANTIBODIES
NIH funds new tuberculosis research advancement centers
Report: WHO technical consultation on innovative clinical trial designs for evaluating new TB preventive treatments
Media Statement: Effect of COVID-19 on Tuberculosis in the U.S.
March 24, 2022 – COVID-19 likely had a substantial effect on U.S. TB disease trends
CROI 2022 TB Round Up
TB disease and deaths declining among people living with HIV, but there have been some reversals due to the COVID-19 pandemic
MSF responds to updated WHO guidelines for tuberculosis in children
Impact of COVID-19 hits hard as TB deaths among people living with HIV rise for the first time since 2006
EU plans to buy measles, polio vaccines for Ukraine refugees
The History of Tuberculosis Holds Lessons For Modern Day Public Health
The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis
Thoracic ultrasound for TB diagnosis in adults and children
Integrated screening and testing for TB and COVID-19 in Peru
INCREASE FUNDING OR ABANDON HOPE OF ENDING MALARIA, TB AND AIDS
Global Fund Approves Emergency Funding to Maintain Essential HIV and TB Services in Ukraine
Multi-center clinical trial launched to investigate new treatment for pediatric type 1 diabetes
Worrying lack of funding for tuberculosis
What is the evidence on existing national policies and guidelines for delivering effective tuberculosis, HIV and viral hepatitis services for refugees and migrants among Member States of the WHO European Region? (2022)
European Commitments to TB R&D Investments: Promises Made to Be Broken?
The impact of COVID-19 on TB: a review of the data
Third round of the global pulse survey on continuity of essential health services during the COVID-19 pandemic
Advocates call on Indian government to stop using injectable agents for the treatment of drug-resistant TB
MedMira Receives CE Marking for its REVEALCOVID-19® PLUS Total Antibody Test
QIAGEN’s new generation TB test gets Chinese approval, renewed WHO backing
IN MEMORIUM
FACT SHEET: The Biden Administration’s Commitment to Global Health
TB Elimination Alliance Impact Report 2020-2021
Pediatric Tuberculosis Research and Development: Progress, Priorities and Funding Opportunities
Can Patents Affect Access to TB Preventative Treatment
Funding for neglected disease research stays stable in 2020 despite COVID-19 pressures
Use of alternative interferon-gamma release assays for the diagnosis of TB infection: WHO policy statement
With tuberculosis resurgent after two years of COVID-19-inspired neglect, TB Alliance is awarded USAID funding to develop new treatments
WHO: State of inequality: HIV, tuberculosis and malaria
Global Fund Applauds Luxembourg’s Contribution to the COVID-19 Response Mechanism
COVID Deaths in 2021 > Combined Death Toll of HIV, TB, Malaria in 2020
It’s time for action on inequality to end TB and AIDS
Use of Xpert MTB/RIF and Xpert MTB/RIF Ultra on GeneXpert 10-colour instruments: WHO POLICY STATEMENT
RESIST-TB November 2021 Newsletter
NCHHSTP Metrics Dashboard: TB Elimination
2021
What’s new in the TB section of the 2021 WHO Model Lists of Essential Medicines
TB bacterium: UAB researcher describe how the exotoxin is secreted and trafficked
Dismal global tuberculosis situation due to COVID-19
U.S., Global Partner Donate Tools to Improve TB Service
GHIT Fund Announces New Investments: A Total of 750 Million Yen in Drugs for Malaria and Chagas Disease, Vaccine for Malaria, and Diagnostics for Tuberculosis
Global Fund Board Approves New Strategy Placing People and Communities at Center to Lead Fight Against HIV, TB, Malaria, to Build Systems for Health, Equity and Strengthen Pandemic Preparedness
ACTG announces launch of clinical trial evaluating a three-month TB treatment
Fighting Pandemics and Building a Healthier and More Equitable World - Global Fund Strategy (2023-2028)
Global Pulmonary Tuberculosis Clinical Trials Report H2, 2021: Phase, Trial Status, End Points Status and Sponsor Type Review - ResearchAndMarkets.com
ACTG Announces Initiation Of CLO-FAST, Its First Trial Evaluating A Three-Month TB Treatment
Research in Action Awards 2021
The Challenge of Diagnosing HIV Infection in LA PrEP Users
PrEPared? Long-Acting PrEP Access in Communities Marginalized by the U.S. Healthcare System
The Lancet Commission on diagnostics: transforming access to diagnostics
Realizing Returns on U.S. Government Investments in GeneXpert Diagnostic Technologies
Long-Acting Therapy for Malaria Prevention: Toward a Malaria-Free World
USAID'S COVID-19 RESPONSE: LATEST NEWS
Terraforming the Policy Landscape to Enable Access to Long-Acting Technologies
Know Your CAB: Community Experts Shaping the Long-Acting Technologies Pipeline
Delivering on the Promise of Long-Acting Technologies
Developing Long-Acting Cures to Accelerate the End of Hepatitis C: Interview with Dr. Dave Thomas
Injectables Redux: Developing Acceptable Long-Acting Formulations for TB Prevention Amidst a Push for All-Oral Treatment
TAG 2021 Pipeline Report Tuberculosis Vaccines
TAG 2021 Pipeline Report Tuberculosis Preventative Treatment
The International Journal of Tuberculosis and Lung Disease
Mapping the Technology Landscape of National TB Programs: Report
Global Lung Health Meet Opens With Top Three Science Announcements
New NACCHO Case Study Series Highlights LHD and Health Center Partnerships to Address TB and COVID-19
WHO Global TB Report Release
People living with HIV who started tuberculosis preventive treatment
Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020
The Medicines Patent Pool secures its first licence on promising long-acting technologies for malaria, tuberculosis, and hepatitis C
Statement on the anniversary of the UN High-Level Meeting on TB
Our Footprint at the 52nd Union World Conference on Lung Health
How Can TB Services for Adolescents and Youth be Improved?
A Critical Chance to End Pediatric TB in the Era of COVID-19
TB Alliance Welcomes New Data on BPaL-Based Regimens Presented at the 2021 Union Conference
Rifampicin-Resistant Tuberculosis (RR-TB), MSF Clinical Trials Present Short And Effective Treatment
WHO Global Tuberculosis Report—New Drugs and Regimens Need to be Combined with Equitable and Universal Access
Press Statement: Calls for Urgent Action to Address TB Prevention Deficits Among Children and Household Contacts of People Affected by TB
Anti-tuberculosis Therapeutics Market: Worldwide Analysis and Forecasts, 2021 to 2024
Organic Dispersion To Drive The Drug Resistant Tuberculosis Treatment Market
Reported Tuberculosis in the United States, 2020
Program Evaluation: Developing and Implementing a Remediation Plan1
CDC: TB Notes 3, 2021 - Notes from the Director
Meeting report: Virtual Global Forum on Tuberculosis Vaccines, 20–22 April 2021
Tuberculosis Vaccines: An Update of Recent and Ongoing Clinical Trials
Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis
TB Alliance Expands Board of Directors
Public Health Action - September 2021
The Medicines Patent Pool secures its first licence on promising long-acting technologies for malaria, tuberculosis, and hepatitis C
Statement on the anniversary of the UN High-Level Meeting on TB
New Report: The Global Impact of Respiratory Disease - 3rd Edition
TB Elimination Alliance Impact Report 2020-2021
BMJ Awards 2021: Respiratory team of the year
Tuberculosis - Annual Epidemiological Report for 2019
Economic impact of tuberculosis mortality in 120 countries and the cost of not achieving the Sustainable Development Goals tuberculosis targets: a full-income analysis
Results Report 2021
Policy Research Report - From Siloes to Synergies: Integrating noncommunicable disease prevention and care into global health initiatives and universal health coverage
Bovine TB: epidemiology reports, 2020
Assembly Side Event: Progress and Multisectoral Action Towards Achieving Global Targets to End TB
A second call for case studies of programmatic innovations to address challenges in TB prevention and care during the COVID-19 pandemic
Where we unite to #EndTB!
Subscribe to the TB WIRE today!
Home
About TB
TB Resources
TB & COVID
Specific Cultural/Language Resources
About
History
Leadership
Partnerships
Action
Join Friends of Stop TB USA
Write a Letter To The Editor
World TB Day
News
TBWire
TB Wire Archive: 2023
TB Wire Archive: 2022
TB in the News
Reports/Updates
Peer-Reviewed Publications
Community
We are TB
TB Photo Voice
Survivor Stories
Contact
Sign up!
DONATE
Market Analyses:
Global Latent Tuberculosis Infection (LTBI) Testing Market Research Report 2022 - ResearchAndMarkets.com
VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market demand and future scope with Russia-Ukraine Crisis Impact Analysis –Vakzine Projekt Management (VPM), Serum Institute of India
Anti-Tuberculosis Drug Market demand and future scope with Russia-Ukraine Crisis Impact Analysis –Lupin, Otsuka, Sanofi, Prizer, Abbott, NOVARTIS
Anti-Tuberculosis Drug Market demand and future scope with Russia-Ukraine Crisis Impact Analysis –Lupin, Otsuka, Sanofi, Prizer, Abbott, NOVARTIS
Tuberculosis Testing Market 2022 By Emerging Trends, Industry Share, Regional Overview and SWOT Analysis till 2027
Tuberculosis Vaccine Treatment Market Size 2021 Analysis by Top Key Players | Sanofi,Merck,Serum Institute of India,GlaxoSmithKline
Tuberculosis (TB) Treatment Market Size 2021 Analysis by Top Key Players | Johnson & Johnson,Otsuka Pharmaceutical Co.,Ltd,Dong-A ST Co.
Tuberculosis Diagnostics Market 2021-2026: Size, Share, Growth, Outlook and Forecast
Anti-tuberculosis Therapeutics 2021 Market by Manufacturers, Regions, Type and Application, Forecast to 2024
Tuberculosis Diagnosis and Treatment Market Size, Key Company Profiles, Types, Applications and Forecast To 2027
Tuberculosis Testing Market Report 2021 Market SWOT Analysis,Key Indicators,Forecast 2027 : Abbott Laboratories, Akonni Biosystems, Alere
Tuberculosis Testing Technology Market to Witness Huge Growth by 2028 | Thermo Fisher Scientific, Alere, Epistem
Global Anti-Tuberculosis Therapeutics Market Industry Share, Size And Movements By Growth Status, Trend Analysis To 2020 – 2027 | Leading Players-Macleods Pharmaceuticals Ltd, Pfizer Inc, Hikma Pharmaceuticals PLC, Lannett, Mylan N.V., Teva Pharmaceutical Industries Ltd
Tuberculosis Drugs Market Trends, Top Manufactures, Tuberculosis Drugs Market Demands, Industry Growth Analysis & Forecast 2026
BCG Vaccine Market By Type (Immune BCG, Therapy BCG), Application Type (Hospitals, Clinics, Others), And Region- Global Forecast To 2028
Global BCG Tuberculosis (TB) Vaccine Market: How Much Will Be the Total Production in 2027? with Top Companies Like:Sanofi Pasteur, Japan BCG Lab, China National Biotec
Tuberculosis Testing Market Innovative Strategy by 2028 | Abbott Laboratories, Akonni Biosystems, Abbott
Tuberculosis Drugs Market CAGR by Technology, Key Players, Regions, Cost, Revenue and Forecast to 2028 | ohnson & Johnson Services, LLC, Lupin Ltd, Novartis AG
Tuberculosis Drugs Competitor Analysis Report - Global Forecast to 2026
Tuberculosis Diagnostics Competitor Analysis Report - Global Forecast to 2026
Tuberculosis Testing Competitor Analysis Report - Global Forecast to 2026
Tuberculosis Testing Market Industry Analysis, Geographical Segmentation, Drivers, Challenges, Trends Forecasts Report 2021 -2026 – Hoffmann-La Roche AG, Hain LifeScience GmbH, Hologic Corporation, etc.
Tuberculosis Prevention and Treatment Vaccine Market Size 2021 Growing Rapidly with Upcoming Trends, New Development Strategy, Competitive Landscape and Growth by Forecast 2027
Tuberculosis Vaccines Market Professional Survey 2021 by Manufacturers, Share, Growth, Trends, Types and Applications, Forecast to 2026
Tuberculosis Vaccine Treatment Market Insights, Status, Latest Amendments and Outlook 2021 – 2027 |Top key players: Merck & Co., Inc.(US), Sanofi Pasteur SA (France)
Tuberculosis Vaccine Treatment Market SWOT Analysis,Key Indicators,Forecast 2027 : Merck,Japan BCG Lab,Serum Institute of India,AJ Vaccines
Tuberculosis Vaccine Treatment Market Growth Factor Details for Business Development Forecasts 2027 – Serum Institute of India, AJ Vaccines
Tuberculosis Treatment Market 2021-2027 Global Industry Outlook- Sanofi, Bayer, Eli Lilly, Labatec Pharma, Novatis
Tuberculosis Treatment Drugs Market 2021 | Scope of Current and Future Industry 2027
Tuberculosis Testing Market Drivers And Restraints For Each Segment
Tuberculosis Drugs Market Ultimate Analysis by Source, Sales Channel, Formulation & Global Forecast to 2027
Tuberculosis Drugs Market Size 2021 Key Strategies, Applications, Trends and Opportunities
Tuberculosis Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026
Tuberculosis (TB) Treatment Market Size, Latest Trends, Growth and Share 2021 | Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd, Macleods Pharmaceutical Ltd
Mycobacterium Tuberculosis Market Future Outlook of Statistics on Industry Growth till 2026| Thermo Fisher Scientific, Danaher, Mediven, Osang Healthcare, Hologic
GLOBAL TUBERCULOSIS VACCINE TREATMENT MARKET REPORT FUTURE PROSPECTS, GROWTH, OUTLOOK AND FORECAST 2021-2026
Global Tuberculosis Therapeutics Market Statistics, Development and Growth Market Players 2022-2027
Global Tuberculosis Drugs Market Development Prospects 2021-2027 | By Pfizer Inc, Cipla Ltd, AstraZeneca Plc, Novartis AG
Tuberculosis Diagnosis and Treatment Market Size and Industry Analysis Report, by Type, by Application, by Country & Region, and Segment Forecasts, 2016 – 2027
Infectious Disease Molecular Diagnostics Market Size Worth $40.8 Billion By 2028: Grand View Research, Inc.
Tuberculosis Testing Technology Market (2021-2027) Demand Analysis, Global Business Growth | F. Hoffmann-La Roche AG, QIAGEN, Cepheid Inc., Hologic, Sanofi S.A., Abbott Laboratories, BioMérieux, Thermo Fisher Scientific, etc
TB Vaccines Market Major Geographies, Prominent Players Review and Forecast 2021 to 2027
Tuberculosis Treatment Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth
TUBERCULOSIS VACCINE TREATMENT MARKET ANALYSIS BY SIZE, SHARE, GROWTH, APPLICATION, SEGMENTATION AND FORECAST TO 2026
LATENT TUBERCULOSIS TESTING MARKET SHARE TO RECORD ROBUST GROWTH THROUGH 2026
Tuberculosis Testing Market Size,Forecast,and Top Firms : Abbott Laboratories,Akonni Biosystems,Alere,,Becton,Dickinson and Company,Cepheid
Global Tuberculosis (TB) Detection Market Growing Popularity and Emerging Trends 2021-2028 Danaher, Hain Lifescience, Abbott
Global Tuberculosis (TB) Detection Market Growing Popularity and Emerging Trends 2021-2028 Danaher, Hain Lifescience, Abbott
Tuberculosis Treatment Market Size, Share, Future Opportunities 2028 | Sanofi, Otsuka, Labatec Pharma, Bayer, Novatis, Eli Lilly, Pfizer, etc.
Qualitative analysis of Tuberculosis Testing and Diagnostics Market Revenue & Industry Analysis By 2026
Tuberculosis Testing Market research and analysis by expert top companies, growth drivers, industry challenges, and opportunities to 2028
Global Anti-Tuberculosis Therapeutics Market Forecast to 2027 Size, Share, Upcoming Trends Segmentation, Top Players like Lupin, Johnson and Johnson Services Inc, Macleods Pharmaceuticals Ltd, Pfizer Inc, Hikma Pharmaceuticals
Global BCG Tuberculosis Vaccine Market Report Forecast to 2021-27- GREENSIGNAL BIO PHARMA LIMITED, INTERVAX LTD, JAPAN BCG LABORATORY
Tuberculosis Drugs Market to Eyewitness Massive Growth by EIKEN CHEMICAL, Sandoz, Archivel Farma
View on Mobile